Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Consensus Recommendation of “Reduce” from Analysts

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been given an average recommendation of “Reduce” by the seven brokerages that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $14.40.

Several analysts have recently commented on IART shares. Citigroup reduced their price objective on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating for the company in a research report on Wednesday, March 11th. Wells Fargo & Company raised shares of Integra LifeSciences to a “hold” rating in a research note on Wednesday, March 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Finally, Wall Street Zen lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th.

Hedge Funds Weigh In On Integra LifeSciences

A number of large investors have recently modified their holdings of the company. Global Retirement Partners LLC bought a new stake in Integra LifeSciences during the 4th quarter valued at $25,000. GAMMA Investing LLC grew its holdings in shares of Integra LifeSciences by 55.3% during the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after buying an additional 913 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after acquiring an additional 6,814 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Integra LifeSciences during the 4th quarter valued at about $124,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Trading Down 1.5%

NASDAQ IART traded down $0.14 during mid-day trading on Friday, reaching $9.24. 116,859 shares of the stock were exchanged, compared to its average volume of 774,339. The stock has a market cap of $720.14 million, a P/E ratio of -1.37 and a beta of 1.02. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. Integra LifeSciences has a one year low of $8.70 and a one year high of $22.27. The stock has a 50 day simple moving average of $10.73 and a 200-day simple moving average of $12.52.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The firm had revenue of $434.93 million during the quarter, compared to analyst estimates of $429.62 million. During the same period last year, the company posted $0.97 EPS. The business’s quarterly revenue was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.